Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 2.67B | 2.68B | 2.63B | 2.10B | 1.75B | 1.32B |
Gross Profit | 1.47B | 1.87B | 1.85B | 1.45B | 1.26B | 990.42M |
EBITDA | 643.57M | 665.04M | 713.41M | 447.55M | 550.45M | 394.80M |
Net Income | 412.92M | 420.45M | 416.12M | 180.47M | 352.23M | 230.07M |
Balance Sheet | ||||||
Total Assets | 7.13B | 7.12B | 7.11B | 6.89B | 6.95B | 6.30B |
Cash, Cash Equivalents and Short-Term Investments | 2.66B | 2.76B | 2.75B | 2.54B | 2.91B | 3.11B |
Total Debt | 452.51M | 448.43M | 407.95M | 118.26M | 105.51M | 108.08M |
Total Liabilities | 1.18B | 1.20B | 1.09B | 990.02M | 890.07M | 564.46M |
Stockholders Equity | 5.67B | 5.58B | 5.65B | 5.51B | 5.71B | 5.49B |
Cash Flow | ||||||
Free Cash Flow | 254.80M | 283.08M | 367.22M | -85.85M | 70.19M | 66.21M |
Operating Cash Flow | 440.55M | 648.57M | 634.45M | 231.30M | 342.29M | 262.07M |
Investing Cash Flow | -183.48M | 282.28M | -376.65M | -681.82M | -148.09M | 316.92M |
Financing Cash Flow | -511.56M | -390.35M | -257.73M | -288.35M | -231.25M | -190.06M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
70 Outperform | HK$12.15B | 14.48 | 6.98% | 3.99% | -5.62% | -9.71% | |
66 Neutral | 10.87B | 76.05 | 4.02% | ― | 48.38% | 0.00% | |
57 Neutral | 13.49B | -64.48 | -58.53% | ― | 240.05% | -140.09% | |
55 Neutral | 20.69B | -72.04 | -20.82% | ― | 964.40% | 65.90% | |
53 Neutral | 11.68B | -20.40 | 0.00% | ― | 1219.19% | 25.15% | |
46 Neutral | 11.49B | -40.39 | -15.31% | ― | -76.58% | -4.90% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Shanghai Haohai Biological Technology Co., Ltd. has announced an interim cash dividend of RMB 0.4 per share for the six-month period ending June 30, 2025. The dividend will be paid in Hong Kong dollars at an exchange rate of RMB 1 to HKD 1.096155, with a payment date set for October 17, 2025. The announcement reflects the company’s financial health and commitment to returning value to its shareholders. The dividend distribution also involves withholding tax implications for both resident and non-resident shareholders, with varying rates based on residency and applicable tax treaties.
The most recent analyst rating on (HK:6826) stock is a Buy with a HK$33.00 price target. To see the full list of analyst forecasts on Shanghai Haohai Biological Technology Co., Ltd. Class H stock, see the HK:6826 Stock Forecast page.
Shanghai Haohai Biological Technology Co., Ltd. reported a decrease in revenue and profit for the six-month period ending June 30, 2025, compared to the same period in 2024. Revenue fell by approximately 7.48% to RMB1,292.64 million, while profit attributable to ordinary equity holders decreased by 10.29% to RMB211.07 million. Despite these declines, the company maintained its interim dividend at RMB0.40 per share. The decrease in R&D expenses by 21.53% and a slight improvement in other income and gains were notable financial movements during the period.
The most recent analyst rating on (HK:6826) stock is a Buy with a HK$33.00 price target. To see the full list of analyst forecasts on Shanghai Haohai Biological Technology Co., Ltd. Class H stock, see the HK:6826 Stock Forecast page.
Shanghai Haohai Biological Technology Co., Ltd. has announced the distribution and payment of an interim dividend for 2025, amounting to RMB0.40 per share, totaling RMB91,493,200.00. The dividend will be distributed to H Shareholders in Hong Kong Dollars, with payments scheduled for October 17, 2025. The company has also outlined tax arrangements for non-resident enterprise shareholders and individual holders of H shares, ensuring compliance with the Enterprise Income Tax Law of the People’s Republic of China.
The most recent analyst rating on (HK:6826) stock is a Buy with a HK$33.00 price target. To see the full list of analyst forecasts on Shanghai Haohai Biological Technology Co., Ltd. Class H stock, see the HK:6826 Stock Forecast page.
Shanghai Haohai Biological Technology Co., Ltd. has announced that its board of directors will meet on August 22, 2025, to review and approve the interim results for the first half of the year ending June 30, 2025. The meeting will also consider the possibility of declaring an interim dividend, which could impact shareholder returns and reflect the company’s financial health.
Shanghai Haohai Biological Technology Co., Ltd. announced an adjustment to the share price cap for its A shares repurchase plan. The company has reduced the maximum repurchase price to RMB88.72 per share following the approval of its 2024 profit distribution plan and the completion of the final dividend distribution. This adjustment is part of the company’s ongoing strategy to manage its share capital effectively, adhering to relevant regulations and market conditions.
Shanghai Haohai Biological Technology Co., Ltd. has announced the composition of its board of directors, highlighting the roles and functions of each member. The board consists of executive, non-executive, and independent non-executive directors, with various members serving on four key committees: Audit, Remuneration and Review, Nomination, and Strategy and Sustainable Development. This announcement underscores the company’s commitment to structured governance and strategic oversight, potentially impacting its operational efficiency and stakeholder confidence.
Shanghai Haohai Biological Technology Co., Ltd. has established an audit committee to enhance its corporate governance and financial oversight. The committee is responsible for reviewing financial information, supervising audits, and ensuring effective management oversight, which is expected to strengthen the company’s decision-making and governance structure.
Shanghai Haohai Biological Technology Co., Ltd. has established a remuneration and appraisal committee under its Board of Directors to enhance its remuneration management system. This committee is responsible for setting performance evaluation indicators and remuneration systems for directors and senior management, ensuring a formal and transparent process for developing remuneration policies, and making recommendations on remuneration packages. The move aims to align the company’s governance with regulatory requirements and improve oversight of executive compensation, potentially impacting its market positioning and stakeholder confidence.
Shanghai Haohai Biological Technology Co., Ltd. has established a Nomination Committee under its Board of Directors to enhance corporate governance. This committee is responsible for setting criteria and procedures for selecting directors and senior management, ensuring the board’s composition aligns with the company’s strategic goals, and maintaining board diversity. This move aims to optimize board operations and improve decision-making processes, which could strengthen the company’s industry positioning and stakeholder confidence.
Shanghai Haohai Biological Technology Co., Ltd. successfully held its Annual General Meeting and class meetings for A and H shareholders, where all proposed resolutions were approved. Significant decisions included the 2024 profit distribution, election of a new board session, and the abolishment of the supervisory committee, which are expected to impact the company’s governance and operational strategies.